For Dr. Rebecca Ruck, having more women in science is personal. She remembers times early in her career when she was the only woman in the room. That’s why she co-founded the Merck Research Award
28.02.2023 - Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today provided updates on two Phase 3 trials, KEYNOTE-641 and KEYNOTE-789. Merck is discontinuing the Phase 3 KEYNOTE-641 trial evaluating KEYTRUDA (pembrolizumab), Merck’s .
22.02.2023 - Merck (NYSE: MRK), known as MSD outside of the United States and Canada, announced today that the company has opened enrollment in its new Phase 3 clinical program with investigational once-daily islatravir 0.25 mg in combination with doravirine 100 . Seite 1
21.02.2023 - Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced that LAGEVRIO (molnupiravir) did not demonstrate a statistically significant reduction in the risk of COVID-19 following household exposure to another individual .